Další formáty:
BibTeX
LaTeX
RIS
@article{1717482,
author = {Malík, Ivan and Kováč, Gustav and Padrtová, Tereza and Hudecová, Lucia and Kováč, Gustav and Padrtová, Tereza and Hudecová, Lucia},
article_number = {3},
keywords = {SARS-CoV-2 • COVID-19 • ingavirin • heterogeneous nuclear ribonucleoproteins • nucleocapsid (N) protein},
language = {eng},
issn = {1210-7816},
journal = {Česká a slovesnká farmacie},
title = {Ingavirín môže byť sľubnou zlúčeninou v boji proti koronavírusu 2 vyvolávajúcemu ťažký akútny respiračný syndróm (SARS-CoV-2)},
url = {https://www.prolekare.cz/casopisy/ceska-slovenska-farmacie/2020-3-10/ingavirin-moze-byt-slubnou-zluceninou-v-boji-proti-koronavirusu-2-vyvolavajucemu-tazky-akutny-respiracny-syndrom-sars-cov-2-123699},
volume = {69},
year = {2020}
}
TY - JOUR
ID - 1717482
AU - Malík, Ivan - Kováč, Gustav - Padrtová, Tereza - Hudecová, Lucia - Kováč, Gustav - Padrtová, Tereza - Hudecová, Lucia
PY - 2020
TI - Ingavirín môže byť sľubnou zlúčeninou v boji proti koronavírusu 2 vyvolávajúcemu ťažký akútny respiračný syndróm (SARS-CoV-2)
JF - Česká a slovesnká farmacie
VL - 69
IS - 3
SP - 107-111
EP - 107-111
SN - 12107816
KW - SARS-CoV-2 • COVID-19 • ingavirin • heterogeneous nuclear ribonucleoproteins • nucleocapsid (N) protein
UR - https://www.prolekare.cz/casopisy/ceska-slovenska-farmacie/2020-3-10/ingavirin-moze-byt-slubnou-zluceninou-v-boji-proti-koronavirusu-2-vyvolavajucemu-tazky-akutny-respiracny-syndrom-sars-cov-2-123699
L2 - https://www.prolekare.cz/casopisy/ceska-slovenska-farmacie/2020-3-10/ingavirin-moze-byt-slubnou-zluceninou-v-boji-proti-koronavirusu-2-vyvolavajucemu-tazky-akutny-respiracny-syndrom-sars-cov-2-123699
N2 - The Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease-19 (COVID-19) pandemic, caused by the virus, have changed the world in just half a year. Lack of effective treatment, coupled with etiology of COVID-19, has resulted in more than 500,000 confirmed deaths at the time of writing, and the global economy is at an unseen unprecedented low level with unknown near- and long-term consequences. Ingavirin has been considered a non-toxic broad-spectrum antiviral with a complex mechanism of action. The molecule was originally designed for the prophylaxis and treatment of flu caused by both Influenza A and B viruses and for the treatment of viral causes of acute respiratory illness. The article hypothesized that the efficiency of given 1H-imidazol-4-yl heterocyclic scaffold-containing compound against SARS-CoV-2 might be connected with its ability to interfere with specific heterogeneous nuclear ribonucleoproteins (A1, for example). These specific cellular RNA-binding proteins showed affinity to Severe Acute Respiratory Coronavirus (SARS-CoV) nucleocapsid (N) protein, which shared high homology with the N protein of SARS-CoV-2 and the fact was expressed by a sequence identity of 90.52%. Impairing of the interactions between nuclear ribonucleoproteins and nucleocapsid (N) protein of SARS-CoV-2 might result in the inhibition of a viral replication cycle. Additional immunomodulating properties of ingavirin could be favorable for induction of adaptive immunity of host cells.
ER -
MALÍK, Ivan, Gustav KOVÁČ, Tereza PADRTOVÁ a Lucia HUDECOVÁ. Ingavirín môže byť sľubnou zlúčeninou v boji proti koronavírusu 2 vyvolávajúcemu ťažký akútny respiračný syndróm (SARS-CoV-2). \textit{Česká a slovesnká farmacie}. 2020, roč.~69, č.~3, s.~107-111. ISSN~1210-7816.
|
